JPRN-jRCT2031200133已完成1 期
A PHASE I SINGLE CENTER, OPEN-LABEL, COMBINATION STUDY OF RM-1929 AND PHOTOIMMUNOTHERAPY IN PATIENTS WITH RECURRENT SQUAMOUS CELL HEAD AND NECK CANCER
Arron Sarah0 个研究点目标入组 3 人开始时间: 2020年9月30日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 3
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients must meet the following criteria to be eligible for study participation:
- •1. Patients with histologically confirmed recurrent squamous carcinoma of the head and neck, who in the opinion of their treating physician, cannot be satisfactorily treated with surgery, radiation, or platinum chemotherapy and who do not have other options for standard of care treatments.
- •2. Patients must have received prior systemic platinum-based chemotherapy for treatment of their head and neck cancer, unless in the opinion of the medical oncologist, the use of platinum-based chemotherapy is contraindicated or not recommended, e.g., renal impairment, allergy to platinum compounds, age, liver disease, myelosuppression, neuropathy, hearing loss, etc.
- •3. Life expectancy > 4 months based on investigator judgement.
- •4. Male or female patients at least 18 years old; when the subject under 20 years old, informed consent will be obtained from both the subject and his/her legal guardian.
- •5. Patients must have an ECOG score of 0 - 2.
- •6. When the subject under 20 years old, informed consent will be obtained from both the subject and his/her legal guardian.
排除标准
- •Patients with any of the following will be excluded from participation in the study:
- •1. Patients with a history of significant Erbitux infusion reactions (>=Grade 3).
- •2. Patients on chemotherapy or Erbitux therapy or radiation therapy within 4 weeks of enrollment.
- •3. Tumor invading a major blood vessel (such as the carotid artery) unless the vessel has been embolized, stented or surgically ligated to prevent hemorrhage.
- •4. Tumor is not clearly shown on a CT scan with contrast (MRI with gadolinium if CT not appropriate) or clinically measurable.
- •5. Location and extension of the tumor precludes effective Photoimmunotherapy (PIT).
- •6. Patients with impaired hepatic function, ALP (hepatic), AST and/or ALT >3 times the upper limit of normal, and total serum bilirubin >2 mg/dL.
- •7. Patients with impaired renal function (serum creatinine >2 mg/dL).
- •8. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- •9. Patient requires examinations or treatments within 4 weeks after study drug administration where they would be exposed to significant light, e.g., eye examinations, surgical procedures, endoscopy, etc.
- •10. Unwilling or unable to follow protocol requirements.
- •11. Any condition which in the Investigator's opinion deems the patient an unsuitable candidate to receive study drug.
研究者
相似试验
已完成
3 期
CLINICAL STUDY EVALUATING EFFICACY AND SAFETY OFINTRAMUSCULAR INJECTION OF PARACETAMOL 500MG/ 2ML IN THE MANAGEMENT OF FEVERCTRI/2021/01/030201Troikaa Pharmaceuticals Ltd
进行中（未招募）
1 期
A PHASE II, OPEN LABEL, RANDOMISED, SINGLE CENTRE STUDY TO EVALUATE THE SAFETY, REACTOGENICITY AND IMMUNOGENICITY OF THREE OR FOUR DOSES OF MENINGOCOCCAL SEROGROUP B OUTER MEMBRANE VESICLE (OMV) VACCINE MENZBTM WHEN ADMINISTERED TO HEALTHY ADULTS (UNIVERSITY STUDENTS)Prevention of invasive disease caused by N. meningitidis serogroup BEUCTR2005-003570-22-GBHealth Protection Agency
进行中（未招募）
1 期
A Phase Ib, Single Centre, Open Label, Parallel-Group, Controlled Study of Effects on Metabolic Control of an Oral Insulin Formulation in a Type 2 Diabetic Population. - 24 hour oral insuliType 2 diabetesMedDRA version: 8.1 Level: LLT Classification code 10045242 Term: Type II diabetes mellitusEUCTR2006-006251-12-GBDiabetology Ltd6
已完成
1 期
Pilot clinical investigation of alveolar ridge augmentation using 3-D scaffold matrixCTRI/2019/10/021532Indian Institute of Technology Bombay20
进行中（未招募）
不适用
urasidone for the treatment of schizophrenia in paediatric patientsMedDRA version: 14.1Level: LLTClassification code 10001064Term: Acute schizophreniaSystem Organ Class: 100000004873schizophreniaEUCTR2013-001523-39-Outside-EU/EEASunovion Pharmaceuticals Inc.100